Skip to main content

What the FDA labels say about taking them together

Everolimus and ivacaftor/lumacaftor

Ivacaftor/lumacaftor's FDA label of March 24, 2026 names everolimus in its drug interactions section; the everolimus labels PlainMeds reads (2) do not name ivacaftor/lumacaftor. The ivacaftor/lumacaftor label: “Immunosuppressants: cyclosporine, everolimus, sirolimus, and tacrolimus (avoid the use of ORKAMBI).”

Check it at the source: the everolimus FDA label on DailyMed (effective June 1, 2026, Novartis Pharmaceuticals Corporation); the ivacaftor/lumacaftor FDA label on DailyMed (effective March 24, 2026, Vertex Pharmaceuticals Incorporated).

What does the everolimus label say about ivacaftor/lumacaftor?

Everolimus's label (effective June 1, 2026) and its 1 other brand-application label do not name ivacaftor/lumacaftor in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Afinitor), Novartis Pharmaceuticals Corporation, effective June 1, 2026 (SPL set 2150f73a-179b-4afc-b8ce-67c85cc72f04), via openFDA; the full label on DailyMed

What does the ivacaftor/lumacaftor label say about everolimus?

Ivacaftor/lumacaftor label, drug interactions

Immunosuppressants: cyclosporine, everolimus, sirolimus, and tacrolimus (avoid the use of ORKAMBI).

Source: FDA drug label (ORKAMBI), Vertex Pharmaceuticals Incorporated, effective March 24, 2026 (SPL set 3fc1c40e-cfac-47a1-9e1a-61ead3570600), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

14Everolimus generic labelers
0Ivacaftor/lumacaftor generic labelers
EverolimusIvacaftor/lumacaftor
Labeled forBreast cancer, Seizures and epilepsy, Organ transplant rejectionn/a
Boxed warningNoNo
Pharmacy cost (NADAC)$26.32 per tablet 10 mg tabletn/a
Shortage nowA presentation being discontinuedNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?